Cytori Therapeutics Inc (CYTX) Shares are Down -5.99%

Cytori Therapeutics Inc (CYTX) has risen sharply, recording gains of 1.49% in the past 4 weeks. However, the stock has corrected -5.99% in the past 1 week, providing a good buying opportunity on dips. Cytori Therapeutics Inc (CYTX) : During the past 4 weeks, traders have been relatively bearish on Cytori Therapeutics Inc (CYTX), hence the stock is down -0.97% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.39% relative to the S&P 500.

Cytori Therapeutics Inc (NASDAQ:CYTX): The stock opened at $2.18 on Friday but the bulls could not build on the opening and the stock topped out at $2.18 for the day. The stock traded down to $2.03 during the day, due to lack of any buying support eventually closed down at $2.04 with a loss of -6.42% for the day. The stock had closed at $2.18 on the previous day. The total traded volume was 227,834 shares.

The stock has recorded a 20-day Moving Average of 0.92% and the 50-Day Moving Average is 6.96%. Cytori Therapeutics, Inc. has dropped 45.6% during the last 3-month period . Year-to-Date the stock performance stands at -28.42%.

Cytori Therapeutics Inc (CYTX) : The highest level Cytori Therapeutics Inc (CYTX) is projected to reach is $11 for the short term and the lowest estimate is at $5. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $8 and the possibility the share price can swing is $4.24.


Cytori Therapeutics, Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals, clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan and other regions. The Company offers ECCO-50, a cure for knee osteoarthritis, which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50, a cure for urinary incontinence, which is in Phase II/III of development. The Company is also developing DCCT-10, a cure for cutaneous thermal injury.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.